Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJA1ZO)

• DTT Name: ITGB3 messenger RNA (ITGB3 mRNA) DTT Info
• Gene Name: ITGB3

Molecule-Related Drug & Molecule List

10 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEMILOFIBAN	DMBRYT8	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 3	[1]
DMP-802	DMDK6HP	N. A.	N. A.	Discontinued in Phase 1	[2]
DMP-757	DMGNUXC	N. A.	N. A.	Terminated	[3]
L-709780	DMB3ZTI	N. A.	N. A.	Terminated	[4]
L-738167	DMO69X8	N. A.	N. A.	Terminated	[2]
Ro-43-5054	DMPNHF0	N. A.	N. A.	Terminated	[2]
Ro-43-8857	DM4VY8S	N. A.	N. A.	Terminated	[2]
SB-223245	DM3JQCF	N. A.	N. A.	Terminated	[5]
SC-47643	DMIE039	N. A.	N. A.	Terminated	[6]
SKF-107260	DMM8F0V	N. A.	N. A.	Terminated	[7]

67 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	DMY4VX2	Discovery agent	N.A.	Investigative	[8]
3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	DM2K51S	Discovery agent	N.A.	Investigative	[8]
3-(3-(carbamoyl)benzamido)propanoic acid	DM31JAZ	Discovery agent	N.A.	Investigative	[8]
Ac-Asp-Arg-Leu-Asp-Ser-OH	DMYHADT	Discovery agent	N.A.	Investigative	[9]
AcDRGDS	DM9MDBO	Discovery agent	N.A.	Investigative	[10]
C(-GRGDfL-)	DMTMJAI	Discovery agent	N.A.	Investigative	[11]
C(Arg-Gly-Asp-D-Phe-Val)	DMHNZGP	Discovery agent	N.A.	Investigative	[12]
C(RGDfF)	DMMBESU	Discovery agent	N.A.	Investigative	[13]
C(RGDfMeF)	DM8DU42	Discovery agent	N.A.	Investigative	[13]
C-[-Arg-Gly-Asp-Acpca30-]	DML0U8B	Discovery agent	N.A.	Investigative	[14]
C-[-Arg-Gly-Asp-Acpca31-]	DMKENFU	Discovery agent	N.A.	Investigative	[14]
C-[-Arg-Gly-Asp-Acpca32-]	DMVM7B2	Discovery agent	N.A.	Investigative	[14]
C-[-Arg-Gly-Asp-Acpca33-]	DMIBGWO	Discovery agent	N.A.	Investigative	[14]
Cyclo(RGDfV) (control)	DM3QVOB	Discovery agent	N.A.	Investigative	[15]
Cyclo-[-Arg-Gly-Asp-Amp21-]	DMVXPUB	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp22-]	DMBELJK	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp23-]	DMT29VJ	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp24-]	DM35ZLK	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp25-]	DMEIXUQ	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp26-]	DME5HRW	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp27-]	DMBNJZ0	Discovery agent	N.A.	Investigative	[16]
Cyclo-[-Arg-Gly-Asp-Amp28-]	DMJMHAV	Discovery agent	N.A.	Investigative	[16]
CYCLORGDFV	DMGZ0KM	N. A.	N. A.	Investigative	[17]
Cyclo[RGDfK(cypate)]	DMWYFLD	Discovery agent	N.A.	Investigative	[15]
Cypate-[(RGD)2-NH2]1	DMBTU7G	Discovery agent	N.A.	Investigative	[15]
Cypate-[(RGD)2-NH2]2	DMJNW9P	Discovery agent	N.A.	Investigative	[15]
Cypate-[(RGD)3-NH2]1	DMWINK5	Discovery agent	N.A.	Investigative	[15]
Cypate-[(RGD)3-NH2]2	DM1SAIX	Discovery agent	N.A.	Investigative	[15]
Cypate-[(RGD)4-NH2]1	DM3GLMP	Discovery agent	N.A.	Investigative	[15]
Cypate-[(RGD)4-NH2]2	DMR74OM	Discovery agent	N.A.	Investigative	[15]
C[-Arg-Gly-Asp-Acpca19-]	DMPOIDK	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca20-]	DMJVW1N	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca21-]	DMXCUDV	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca22-]	DM6DV90	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca34-]	DMKHSAV	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca35-]	DMQOY3J	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca36-]	DM7LCPW	Discovery agent	N.A.	Investigative	[14]
C[RGD-(R)-alpha-TfmfV]	DMF091Y	Discovery agent	N.A.	Investigative	[13]
C[RGD-(S)-alpha-TfmfV]	DMC9G2Y	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(R)-alpha-TfmF]	DMXA0JB	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(R)-alpha-TfmV]	DM8FGMA	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(R)-N-Me-alpha-TfmF]	DM4ZWOD	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(S)-alpha-TfmF]	DMCXJOL	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(S)-alpha-TfmV]	DMLRYXK	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(S)-N-Me-alpha-TfmF]	DMNS3HC	Discovery agent	N.A.	Investigative	[13]
C[RGDf-(S,R)-alpha-Dfm-F]	DMAILK8	Discovery agent	N.A.	Investigative	[13]
E[c(RGDyK)]2	DM76UJY	Discovery agent	N.A.	Investigative	[18]
E[c(RGDyK)]2-PTX conjugate	DMS1LZI	Discovery agent	N.A.	Investigative	[18]
Gly-Arg-Gly-Asp-Ser	DMACT8D	Discovery agent	N.A.	Investigative	[19]
Gly-Arg-Gly-Asp-Ser-Pro-Lys	DMGOIME	Discovery agent	N.A.	Investigative	[20]
ISIS 196103	DM1NJD7	Discovery agent	N.A.	Investigative	[21]
ISIS 25237	DMD75MP	Discovery agent	N.A.	Investigative	[21]
ISONIPECOTAMIDE	DM5DKUY	Discovery agent	N.A.	Investigative	[22]
L-734115	DMDNVTF	Discovery agent	N.A.	Investigative	[2]
L-739758	DM5IAXN	Discovery agent	N.A.	Investigative	[2]
L-746233	DMRC8MT	Discovery agent	N.A.	Investigative	[2]
L-750034	DM9QAP4	Discovery agent	N.A.	Investigative	[23]
L-756568	DMEQWSB	Discovery agent	N.A.	Investigative	[2]
L-767679	DM96SPJ	Discovery agent	N.A.	Investigative	[2]
N-(3,5-dichlorophenyl)imidodicarbonimidic diamide	DMQ0LF2	Discovery agent	N.A.	Investigative	[24]
RGDechi	DMX4JN6	Discovery agent	N.A.	Investigative	[12]
ROXIFIBAN	DMWUAMQ	Discovery agent	N.A.	Investigative	[2]
RWJ-53419	DMAEWMP	Discovery agent	N.A.	Investigative	[25]
SB-207043	DM704TL	Discovery agent	N.A.	Investigative	[7]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[26]
SC-54701A	DM3BEKV	Discovery agent	N.A.	Investigative	[27]
ST-1646	DMR1G40	Discovery agent	N.A.	Investigative	[16]

References

• [1] Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
• [2] Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
• [3] Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
• [4] Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
• [5] Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
• [6] Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
• [7] Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
• [8] Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
• [9] Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
• [10] Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33.
• [11] Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
• [12] Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20.
• [13] Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
• [14] Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
• [15] Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75.
• [16] Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.
• [17] Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18.
• [18] Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
• [19] alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43.
• [20] N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40.
• [21] US patent application no. 7,425,545, Modulation of C-reactive protein expression.
• [22] Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32.
• [23] Molecular model of the alpha(IIb)beta(3) integrin. J Med Chem. 2003 Dec 4;46(25):5316-25.
• [24] Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53.
• [25] 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22.
• [26] 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
• [27] Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. J Med Chem. 1997 Aug 29;40(18):2843-57.